- Home>
- Journal Watch
- >
- aromatase inhibitors
Search for aromatase inhibitors in all Journal Watch editions
Physician-authored summaries on the latest research on aromatase inhibitors, editorials on aromatase inhibitors, and perspectives on aromatase inhibitors - drawn from the top medical journals.
Sort by:
Items 1 to 20 of 66 results - Relevance
- Date
You searched for: aromatase inhibitors
-
Preventing Osteoporotic Fractures in Women Who Receive Aromatase Inhibitors
- March 29, 2012
- Andrew M. Kaunitz, MD
- Women's Health
A cost-effectiveness model suggested bisphosphonates should be used only when BMD assessment shows elevated fracture risk.- Reviewing:
- Ito K et al., J Clin Oncol 2012 Feb 27;: Dhesy-Thind SK., J Clin Oncol 2012 Feb 27;:
-
Minimizing Bone Loss Related to Therapy with Aromatase Inhibitors Free
- September 30, 2008
- William J. Gradishar, MD
- Oncology and Hematology
Denosumab seemed protective against AI-induced bone loss in women with early-stage breast cancer.- Reviewing:
- Ellis GK et al., J Clin Oncol 2008 Aug 25;:
-
Aromatase-Inhibitor–Induced Joint Complaints: An Underappreciated Problem?
- October 16, 2007
- William J. Gradishar, MD
- Oncology and Hematology
Joint complaints are common among women who receive AIs.- Reviewing:
- Crew KD et al., J Clin Oncol 2007 Sep 1; 25:3877.
-
Joint Symptoms in Women Taking Aromatase Inhibitors for Breast Cancer
- September 27, 2007
- Allan S. Brett, MD
- General Medicine
Patients who received aromatase inhibitors commonly reported joint symptoms.- Reviewing:
- Crew KD et al., J Clin Oncol 2007 Sep 1; 25:3877.
-
Letrozole vs. Tamoxifen for Early Breast Cancer
- February 7, 2006
- Andrew M. Kaunitz, MD
- Women's Health
The American Society of Clinical Oncology recommends that aromatase inhibitors be used as adjuvant therapy in women with hormone-receptor–positive breast cancer, either as initial therapy . . .- Reviewing:
- , N Engl J Med 2005 Dec 29; 353:2747-57. Swain SM., N Engl J Med 2005 Dec 29; 353:2807-9.
-
Sexual Dysfunction with Aromatase Inhibitor Therapy: An Underestimated Problem?
- February 14, 2013
- Andrew M. Kaunitz, MD
- Women's Health
Swedish study shows AI use is associated with low sexual desire, inadequate vaginal lubrication, and sexual dissatisfaction.- Reviewing:
- Baumgart J et al., Menopause 2013 Feb; 20:162. Bradford A., Menopause 2013 Feb; 20:128.
-
The AI War is Over: It's a Tie
- February 12, 2013
- William J. Gradishar, MD
- Oncology and Hematology
A new study adds to the evidence that outcomes are similar among aromatase inhibitors for postmenopausal women with hormone-sensitive breast cancer.- Reviewing:
- Goss PE et al., J Clin Oncol 2013 Jan 28;:
-
Does Obesity Attenuate Aromatase Inhibition?
- September 4, 2012
- William J. Gradishar, MD
- Oncology and Hematology
Estrogen suppression was less complete in obese women and was significantly greater with letrozole than with anastrozole across all weight groups.- Reviewing:
- Folkerd EJ et al., J Clin Oncol 2012 Aug 20; 30:2977. Ligibel JA and Winer EP., J Clin Oncol 2012 Aug 20; 30:2940.
-
Aromatase Inhibitors for Breast Cancer
- February 3, 2011
- Diane E. Judge, APN/CNP
- Women's Health
For menopausal women who develop breast cancer, drugs called aromatase inhibitors can prevent new or recurring breast cancer. -
Adjuvant Endocrine Therapy for Women with Hormone Receptor–Positive Breast Cancer: Update from the American Society of Clinical Oncology Free
- July 29, 2010
- Andrew M. Kaunitz, MD
- Women's Health
New guidelines emphasize use of aromatase inhibitors, whether alone or sequentially with tamoxifen.- Reviewing:
- Burstein HJ et al., J Clin Oncol 2010 Jul 12;:
-
New Medical Approach to Shrinking Uterine Fibroids?
- April 15, 2010
- Andrew M. Kaunitz, MD
- Women's Health
Aromatase inhibitor therapy reduced fibroid size in reproductive-aged women.- Reviewing:
- Parsanezhad ME et al., Fertil Steril 2010 Jan; 93:192.
-
Does Adjuvant Antiestrogen Therapy Affect Cognitive Function in Women with Hormone-Sensitive Breast Cancer?
- February 25, 2010
- Andrew M. Kaunitz, MD
- Women's Health
Tamoxifen, but not the aromatase inhibitor exemestane, was associated with diminished verbal memory and executive functioning.- Reviewing:
- Schilder CM et al., J Clin Oncol 2010 Feb 8;:
-
How Well Do Breast Cancer Patients Adhere to Adjuvant Therapy?
- March 31, 2009
- William J. Gradishar, MD
- Oncology and Hematology
Patient-reported adherence to tamoxifen and anastrozole was significantly inflated.- Reviewing:
- Ziller V et al., Ann Oncol 2009 Mar; 20:431.
-
Meeting Report: The 2008 San Antonio Breast Cancer Symposium
- January 20, 2009
- William J. Gradishar, MD
- Oncology and Hematology
A summary of the latest findings in breast cancer research -
When Hot Flashes Are Good News
- December 4, 2008
- Andrew M. Kaunitz, MD
- Women's Health
Menopausal symptoms associated with anti-estrogen therapy predicted lower risk for breast cancer recurrence.- Reviewing:
- Cuzick J et al., Lancet Oncol 2008 Dec; 9:1143.
-
Aromatase Inhibitors and Arthralgias
- August 7, 2008
- Andrew M. Kaunitz, MD
- Women's Health
Characterizing the joint pain associated with adjuvant aromatase inhibitors in postmenopausal women with early breast cancer- Reviewing:
- Morales L et al., J Clin Oncol 2008 Jul 1; 26:3147. Hershman DL., J Clin Oncol 2008 Jul 1; 26:3120.
-
Pharmacogenomics, CYP2D6, and Adjuvant Endocrine Therapy
- May 13, 2008
- William J. Gradishar, MD
- Oncology and Hematology
CYP2D6 genotype data could help tailor hormonal therapy for postmenopausal breast cancer patients.- Reviewing:
- Punglia RS et al., J Natl Cancer Inst 2008 May 7; 100:642.
-
More Data on Aromatase Inhibitors for Breast Cancer
- May 8, 2008
- Allan S. Brett, MD
- General Medicine
Extending endocrine therapy beyond 5 years prevents some breast cancer relapses.- Reviewing:
- Muss HB et al., J Clin Oncol 2008 Apr 20; 26:1956. Mamounas EP et al., J Clin Oncol 2008 Apr 20; 26:1965. Goss PE et al., J Clin Oncol 2008 Apr 20; 26:1948.
-
Bone Safety in Women Taking Aromatase Inhibitors
- April 17, 2008
- Andrew M. Kaunitz, MD
- Women's Health
Check BMD at baseline, and consider concomitant bisphosphonate treatment for women with osteopenia.- Reviewing:
- Eastell R et al., J Clin Oncol 2008 Mar 1; 26:1051.
-
Adjuvant Aromatase Inhibitor Treatment for Breast Cancer: Is the Advantage Durable?
- February 7, 2008
- Andrew M. Kaunitz, MD
- Women's Health
At 100 months of follow-up, trial results continued to favor initial treatment with the aromatase inhibitor anastrozole over tamoxifen.- Reviewing:
- Arimidex T, Alone or in Combination (ATAC) Trialists’ Group., Lancet Oncol 2008 Jan; 9:45.
Sort by:
Items 1 to 20 of 66 results - Relevance
- Date
